-
Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
By Fraiser Kansteiner Nov 14, 2024 2:13pm As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again adjusting its insulin production priorities. “To address our current capacity constraints and reach more people with diabetes with our products in the future, our human insulin, which is currently delivered…
November 2024
Archive
Categorise
Recent Posts
- Citing ‘capacity constraints,’ Novo Nordisk plots global wind-down of human insulin pen production
- NIH, MSKCC researchers publish AI model for predicting immunotherapy responses
- ASCO: Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop
- Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
- 8 Biotech Companies in Chicago Cultivating the City’s Life Sciences Scene
